Robeco Institutional Asset Management B.V. Has $19.67 Million Stock Position in ResMed Inc. $RMD

Robeco Institutional Asset Management B.V. lowered its holdings in shares of ResMed Inc. (NYSE:RMD) by 13.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 71,855 shares of the medical equipment provider’s stock after selling 11,596 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in ResMed were worth $19,669,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of RMD. SJS Investment Consulting Inc. raised its position in ResMed by 1,433.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 86 shares during the last quarter. WFA of San Diego LLC acquired a new stake in shares of ResMed in the second quarter valued at about $26,000. GoalVest Advisory LLC bought a new position in shares of ResMed during the third quarter worth about $37,000. Harbour Investments Inc. lifted its stake in shares of ResMed by 264.2% in the second quarter. Harbour Investments Inc. now owns 244 shares of the medical equipment provider’s stock worth $63,000 after acquiring an additional 177 shares during the period. Finally, Virtus Advisers LLC bought a new stake in ResMed in the second quarter valued at approximately $77,000. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on RMD. Weiss Ratings restated a “hold (c+)” rating on shares of ResMed in a report on Monday, December 29th. Royal Bank Of Canada boosted their target price on shares of ResMed from $300.00 to $303.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Robert W. Baird reissued a “neutral” rating and issued a $275.00 price objective (down from $300.00) on shares of ResMed in a research report on Tuesday, December 16th. Morgan Stanley set a $305.00 target price on ResMed in a research report on Friday, October 31st. Finally, Baird R W cut ResMed from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, ResMed has an average rating of “Moderate Buy” and a consensus target price of $296.09.

Insiders Place Their Bets

In other ResMed news, Director Witte Jan De sold 2,055 shares of the company’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $255.00, for a total transaction of $524,025.00. Following the transaction, the director owned 4,261 shares in the company, valued at approximately $1,086,555. This represents a 32.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $251.47, for a total transaction of $502,940.00. Following the transaction, the director owned 68,773 shares of the company’s stock, valued at $17,294,346.31. This represents a 2.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 19,594 shares of company stock worth $4,905,835. Insiders own 0.65% of the company’s stock.

ResMed Stock Performance

Shares of ResMed stock opened at $250.90 on Friday. The business has a 50-day simple moving average of $248.33 and a 200 day simple moving average of $263.17. ResMed Inc. has a one year low of $199.92 and a one year high of $293.81. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.89 and a quick ratio of 2.13. The firm has a market capitalization of $36.62 billion, a price-to-earnings ratio of 25.68, a PEG ratio of 1.67 and a beta of 0.88.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Friday, October 31st. The medical equipment provider reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.49 by $0.06. The business had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. ResMed had a return on equity of 25.45% and a net margin of 27.35%.The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.20 earnings per share. On average, research analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Thursday, November 13th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Thursday, November 13th. ResMed’s payout ratio is 24.56%.

ResMed Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.